» Articles » PMID: 30301464

Profile of Cardiac Lipid Metabolism in STZ-induced Diabetic Mice

Overview
Publisher Biomed Central
Date 2018 Oct 11
PMID 30301464
Citations 17
Authors
Affiliations
Soon will be listed here.
Abstract

Background: Lipotoxicity contributes to diabetic myocardial disease. In this study, we investigated the lipid species contributing to lipotoxicity and the relationship with peroxisomal β-oxidation in the heart of diabetic mice.

Methods: Male C57BL/6 mice were randomly divided into a Diabetic group (intraperitoneal injection of STZ) and a Control group (saline). Cardiac function indexes [ejection fraction (EF%) and fractional shortening (FS%)] were evaluated by echocardiography. Morphological changes in the myocardial tissues and mitochondria were assessed by electron microscopy following hematoxylin and eosin staining. Blood myocardial injury indexes and lipids were measured using an automatic biochemical analyzer. Cardiac ATP levels were analyzed using a commercially available kit. mRNA levels of glucose transporter 4 (GLUT4), fatty acid binding protein 3 (FABP3), palmitoyl transferase 1α (CPT-1α), acyl-CoA oxidase 1 (AOX1), D-bifunctional protein (DBP), 3-ketoacyl-CoA thiolase A (THLA), uncoupling protein (UCP) 2 and UCP3 were investigated by quantitative reverse-transcription polymerase chain reaction. FABP3 protein expression was analyzed by Western blotting. Non-targeted metabolomics by LC-MS/MS was applied to evaluate profile of lipid metabolism in heart.

Results: Compared with controls, EF% and FS% were significantly reduced in diabetic mice. Furthermore, blood myocardial injury indexes and lipids, as well as myocardial mitochondrial cristae fusion were significantly increased. In the diabetic heart, GLUT4 expression was decreased, while expression of FABP3, CPT-1α, AOX1, DBP, THLA, UCP2 and UCP3 was increased, and ATP levels were reduced. In total, 113 lipids exhibited significant differential expression (FC > 2, P < 0.05) between the two groups, with sphingolipid metabolism identified as the top-ranking affected canonical pathway. In the diabetic heart, long-chain hydroxyl-acylcarnitines (8/8) and acylcarnitines (6/11), triglycerides (2/5), and diacyglycerol (3/7) were upregulated, while very long-chain polyunsaturated fatty acids (PUFAs) (5/6) including eicosapentaenoate, docosahexaenoate, phosphocholine (11/19), lysophosphocholine (5/9), phosphoethanolamine (7/11), lysophosphoethanolamine (7/10), phosphatidylglycerol (6/8), phosphoserine (6/8), phosphatidylinositol (2/2), phosphatidic acid (1/1), lysophosphatidic acid (1/1) and sphingomyelin (6/6) were downregulated.

Conclusions: Our data suggest that the increase in toxic lipid species and decreased in PUFAs undergoing peroxisomal β-oxidation, combined with the reduction in phospholipids cause mitochondrial injury and subsequent uncoupling of phosphorylation and ATP deficiency; thereby leading to diabetic heart dysfunction.

Citing Articles

MARK4 aggravates cardiac dysfunction in mice with STZ-induced diabetic cardiomyopathy by regulating ACSL4-mediated myocardial lipid metabolism.

Wu Y, Zhang J, Wang W, Wu D, Kang Y, Fu L Sci Rep. 2024; 14(1):12978.

PMID: 38839927 PMC: 11153581. DOI: 10.1038/s41598-024-64006-7.


Integrated mass spectrometry imaging reveals spatial-metabolic alteration in diabetic cardiomyopathy and the intervention effects of ferulic acid.

Liu Y, Zhang X, Yang S, Zhou Z, Tian L, Li W J Pharm Anal. 2024; 13(12):1496-1509.

PMID: 38223449 PMC: 10785252. DOI: 10.1016/j.jpha.2023.08.011.


A gene therapy targeting medium-chain acyl-CoA dehydrogenase (MCAD) did not protect against diabetes-induced cardiac pathology.

Weeks K, Kiriazis H, Wadley G, Masterman E, Sergienko N, Raaijmakers A J Mol Med (Berl). 2023; 102(1):95-111.

PMID: 37987775 DOI: 10.1007/s00109-023-02397-2.


Phosphatidylglycerol to Treat Chronic Skin Wounds in Diabetes.

Luo Y, Vivaldi Marrero E, Choudhary V, Bollag W Pharmaceutics. 2023; 15(5).

PMID: 37242739 PMC: 10222993. DOI: 10.3390/pharmaceutics15051497.


Potential clinical biomarkers and perspectives in diabetic cardiomyopathy.

Deng J, Yan F, Tian J, Qiao A, Yan D Diabetol Metab Syndr. 2023; 15(1):35.

PMID: 36871006 PMC: 9985231. DOI: 10.1186/s13098-023-00998-y.


References
1.
Carley A, Severson D . Fatty acid metabolism is enhanced in type 2 diabetic hearts. Biochim Biophys Acta. 2005; 1734(2):112-26. DOI: 10.1016/j.bbalip.2005.03.005. View

2.
Stenbit A, Tsao T, Li J, Burcelin R, Geenen D, Factor S . GLUT4 heterozygous knockout mice develop muscle insulin resistance and diabetes. Nat Med. 1997; 3(10):1096-101. DOI: 10.1038/nm1097-1096. View

3.
van de Weijer T, Schrauwen-Hinderling V, Schrauwen P . Lipotoxicity in type 2 diabetic cardiomyopathy. Cardiovasc Res. 2011; 92(1):10-8. DOI: 10.1093/cvr/cvr212. View

4.
Unger R, Clark G, Scherer P, Orci L . Lipid homeostasis, lipotoxicity and the metabolic syndrome. Biochim Biophys Acta. 2009; 1801(3):209-14. DOI: 10.1016/j.bbalip.2009.10.006. View

5.
Shi Y, Sun X, Sun Y, Hou L, Yao M, Lian K . Elevation of cortical C26:0 due to the decline of peroxisomal β-oxidation potentiates amyloid β generation and spatial memory deficits via oxidative stress in diabetic rats. Neuroscience. 2015; 315:125-35. DOI: 10.1016/j.neuroscience.2015.11.067. View